Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KetCRPS-2: Esketamine in CRPS
NCT05212571Enrolling by invitation
- Sponsor
- Erasmus MC
- Start
- Apr 2022
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of esketamine in complex regional pain syndrome (CRPS) (2 arms), sponsored by Erasmus MC. Primary endpoint: Pain Intensity measured by Numerical Rating Scale at 3 months. Started Apr 2022; status: enrolling by invitation.
02
Drugs
esketamine
03
Conditions
complex regional pain syndrome (CRPS)
Beyond the preview
Go deeper on NCT05212571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05212571.